Perrigo Acquires Delsym Generic Version Brand Rights From Tris Pharma
Tris Pharma has a first to file ANDA application for the generic that can entitle it to 180 days of generic exclusivity upon approval. Tris Pharma and Reckitt
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
Novo Nordisk has also taken assistance from the Population Health Research Institute (PHRI) at McMaster University, Canada. Furthermore, an independent data monitoring committee (DMC) is expected to monitor
Nortech Systems said that the Milaca operation specialises in design, manufacturing and post-production services of complex electronic and electromechanical medical devices for diagnostic, analytical and other life-science applications.